Napo Therapeutics Awarded "Best Pharmaceuticals Innovator of the Year - Europe"

Napo Therapeutics, a member of the Jaguar Health family, has been recognized as the "Best Pharmaceuticals Innovator of the Year - Europe" by The European. Based in Milan since 2021, the company focuses on European access to crofelemer, a plant-based prescription drug for rare diseases.

The award highlights Napo's commitment to tackling conditions like microvillus inclusion disease (MVID) and short bowel syndrome (SBS). Ongoing studies in the US and EU are exploring crofelemer's effectiveness for these ailments.

SBS, often linked to intestinal failure, requires costly treatments like parenteral nutrition. Crofelemer aims to improve life for patients with this chronic condition. MVID, affecting infants, results in severe gastrointestinal symptoms with no approved treatments.